Comment from PCCA

Summary: Professional Compounding Centers of America (PCCA) is requesting the removal of two specific proprietary bases, Pracasil-Plus and Loxasperse, from the FDA's Category 3 list of bulk drug substances. They argue that these substances are inactive ingredients and do not meet the regulatory definition of "bulk drug substances," and therefore should not be subject to the Pharmacy Compounding Advisory Committee's review.